InsiderTrades.com logo
F Oliviero III net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

F III Biography and Net Worth

CEO of Checkpoint Therapeutics

Mr. Oliviero is the President and CEO of Checkpoint Therapeutics, a member of Checkpoint’s Board of Directors and has more than twenty years of operational experience in the biotechnology industry. Prior to Checkpoint, Mr. Oliviero served in a variety of leadership roles, most recently as Chief Financial Officer at Keryx Biopharmaceuticals, where he played a key role in growing the company to a market capitalization over $1 billion and completed over $500 million in various public financings. During his time at Keryx, Mr. Oliviero was a leading member of the design of several clinical studies and the regulatory oversight of Keryx’s new drug application for Auryxia™, which successfully obtained FDA marketing approval in 2014 and EMA marketing approval in 2015. Prior to Keryx, Mr. Oliviero was Director of Finance for ACCESS Oncology. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University’s Goizueta Business School.

What is F Oliviero III's net worth?

The estimated net worth of F Oliviero III is at least $16.02 million as of April 2nd, 2025. III owns 3,759,929 shares of Checkpoint Therapeutics stock worth more than $16,017,298 as of December 5th. This net worth approximation does not reflect any other investments that III may own. Additionally, III receives a salary of $921,590.00 as CEO at Checkpoint Therapeutics. Learn More about F Oliviero III's net worth.

How old is F Oliviero III?

III is currently 48 years old. There are 1 older executives and no younger executives at Checkpoint Therapeutics. Learn More on F Oliviero III's age.

What is F Oliviero III's salary?

As the CEO of Checkpoint Therapeutics, Inc., III earns $921,590.00 per year. Learn More on F Oliviero III's salary.

How do I contact F Oliviero III?

The corporate mailing address for III and other Checkpoint Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. Checkpoint Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on F Oliviero III's contact information.

Has F Oliviero III been buying or selling shares of Checkpoint Therapeutics?

F Oliviero III has not been actively trading shares of Checkpoint Therapeutics within the last three months. Most recently, James F. Oliviero III sold 15,090 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $4.04, for a transaction totalling $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at $15,190,113.16. Learn More on F Oliviero III's trading history.

Who are Checkpoint Therapeutics' active insiders?

Checkpoint Therapeutics' insider roster includes William Gray (CFO), and F III (CEO). Learn More on Checkpoint Therapeutics' active insiders.

Are insiders buying or selling shares of Checkpoint Therapeutics?

In the last year, insiders at the sold shares 7 times. They sold a total of 609,748 shares worth more than $2,267,668.30. The most recent insider tranaction occured on April, 2nd when CEO James F Oliviero III sold 15,090 shares worth more than $60,963.60. Insiders at Checkpoint Therapeutics own 2.1% of the company. Learn More about insider trades at Checkpoint Therapeutics.

Information on this page was last updated on 4/2/2025.

F Oliviero III Insider Trading History at Checkpoint Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2025Sell15,090$4.04$60,963.603,759,929View SEC Filing Icon  
2/10/2025Sell10,331$3.15$32,542.653,775,019View SEC Filing Icon  
2/7/2025Sell9,233$3.41$31,484.533,785,350View SEC Filing Icon  
12/19/2024Sell220,230$3.38$744,377.403,194,583View SEC Filing Icon  
6/26/2024Sell24,610$2.05$50,450.501,977,170View SEC Filing Icon  
2/28/2024Sell5,894$2.06$12,141.64350,836View SEC Filing Icon  
2/1/2024Sell11,900$2.01$23,919.00369,680View SEC Filing Icon  
3/2/2023Sell5,483$5.00$27,415.00144,090View SEC Filing Icon  
2/27/2023Sell5,548$4.65$25,798.20134,573View SEC Filing Icon  
2/1/2023Sell10,261$4.77$48,944.97182,121View SEC Filing Icon  
1/10/2023Sell3,817$6.75$25,764.75192,382View SEC Filing Icon  
6/23/2022Sell1,500$11.10$16,650.00256,200View SEC Filing Icon  
6/21/2022Sell2,100$10.90$22,890.00258,900View SEC Filing Icon  
6/17/2022Sell22,800$10.90$248,520.00261,000View SEC Filing Icon  
4/13/2022Sell2,125$15.10$32,087.50283,800View SEC Filing Icon  
4/4/2022Sell8,635$17.90$154,566.50287,329View SEC Filing Icon  
2/4/2021Sell7,000$35.10$245,700.00View SEC Filing Icon  
See Full Table

F Oliviero III Buying and Selling Activity at Checkpoint Therapeutics

This chart shows James F Oliviero III's buying and selling at Checkpoint Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Checkpoint Therapeutics Company Overview

Checkpoint Therapeutics logo
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More

Today's Range

Now: $4.26
Low: $4.26
High: $4.26

50 Day Range

MA: $4.23
Low: $4.15
High: $4.29

2 Week Range

Now: $4.26
Low: $2.06
High: $4.50

Volume

N/A

Average Volume

1,558,467 shs

Market Capitalization

$370.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18